↓ Skip to main content
Embed badge What is this page?

Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer

Overview of attention for article published in BMC Cancer, February 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters

Readers on

mendeley
140 Mendeley

What is this page?

Summary Twitter
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer
Published in
BMC Cancer, February 2013
DOI 10.1186/1471-2407-13-84
Pubmed ID
23433435
Authors

Jolien Heukelom, Olga Hamming, Harry Bartelink, Frank Hoebers, Jordi Giralt, Teresa Herlestam, Marcel Verheij, Michiel van den Brekel, Wouter Vogel, Nick Slevin, Eric Deutsch, Jan-Jakob Sonke, Philippe Lambin, Coen Rasch

Abstract

Failure of locoregional control is the main cause of recurrence in advanced head and neck cancer. This multi-center trial aims to improve outcome in two ways. Firstly, by redistribution of the radiation dose to the metabolically most FDG-PET avid part of the tumour. Hereby, a biologically more effective dose distribution might be achieved while simultaneously sparing normal tissues. Secondly, by improving patient selection. Both cisplatin and Epidermal Growth Factor Receptor (EGFR) antibodies like Cetuximab in combination with Radiotherapy (RT) are effective in enhancing tumour response. However, it is unknown which patients will benefit from either agent in combination with irradiation. We will analyze the predictive value of biological markers and (89)Zr-Cetuximab uptake for treatment outcome of chemoradiation with Cetuximab or cisplatin to improve patient selection.

View on publisher site

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 140 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
France 1 <1%
Unknown 138 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 20 14%
Student > Master 20 14%
Other 16 11%
Researcher 15 11%
Student > Bachelor 15 11%
Other 29 21%
Unknown 25 18%
Readers by discipline Count As %
Medicine and Dentistry 55 39%
Physics and Astronomy 17 12%
Nursing and Health Professions 8 6%
Agricultural and Biological Sciences 5 4%
Biochemistry, Genetics and Molecular Biology 4 3%
Other 12 9%
Unknown 39 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2022.
All research outputs
#13,300,289
of 22,950,943 outputs
Outputs from BMC Cancer
#2,871
of 8,346 outputs
Outputs of similar age
#102,539
of 193,588 outputs
Outputs of similar age from BMC Cancer
#51
of 102 outputs
Altmetric has tracked 22,950,943 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,346 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 193,588 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.